Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Set Alert for Commercial

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases Gastrointestinal

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials Research & Development

Companies

Set Alert for Companies

Latest From Companies

Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras

While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.

Clinical Trials Companies

ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics

Roche looks set to gain first and second place in the race to bring CD3Xcd20s to market – but Genmab and AbbVie have a strong challenger.

Commercial Clinical Trials

Proteome-Focused ProFound Emerges From Flagship Pioneering

The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.

Companies Financing

CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work

Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.

Clinical Trials Commercial

Unicyte’s Unique Stem Cell Approach Could Cure Children With Rare Disorder

Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.

Emerging Company Profile Liver & Hepatic

Pfizer To Learn From Pandemic For Health Equity Initiative

The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.

Market Access Business Strategies
See All

Deals

Set Alert for Deals

Latest From Deals

Torrent Acquires Chronic Brands From Dr. Reddy’s, Folds Up US Liquids Business

Torrent is recalibrating strategy with the addition of chronic therapies from Dr. Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.

Commercial Deals

Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m

Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.

Deal Watch Business Strategies

CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work

Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.

Clinical Trials Commercial

High Hopes For Heidelberg Pharma With Huadong Onboard

CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.

Companies Cancer

Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout

Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

Clinical Trials Gastrointestinal

Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Deals Ophthalmic
See All

Strategy

Set Alert for Strategy

Latest From Strategy

India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs

The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.

Commercial India

High Hopes For Heidelberg Pharma With Huadong Onboard

CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.

Companies Cancer

Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout

Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

Clinical Trials Gastrointestinal

GSK Averts Strike At UK Sites

Companies Manufacturing

Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start

With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial. 

Clinical Trials Neurology

Stock Watch: Biotech’s Commercial Laggards Drag On Sector

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

Stock Watch Commercial
See All

Market Access

Set Alert for Market Access

Latest From Market Access

PBM Formulary Exclusions On The Rise, PhRMA Says

According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval. 

Reimbursement Market Access

Could CAR-Ts Roll Into The Community Setting?

While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space. 

Cancer ImmunoOncology

Pfizer To Learn From Pandemic For Health Equity Initiative

The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.

Market Access Business Strategies
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

PARP Inhibitor Market Dynamics: A Podcast

PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.

Cancer Market Intelligence

Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

Scrip Asks Digital Health

Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.

Scrip Asks Clinical Trials
See All
UsernamePublicRestriction

Register